Investigator On

  • AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2024
  • AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University 2015 - 2022
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • Chronobiology and Chronopharmacology to Prevent Sickle Cell Nephropathy  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • ALTE11C2 Study - Health Effects after Antracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • ALTE11C2-Health Effects after Anthracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University 2016 - 2018
  • Prospective Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT Trial)  awarded by ALL CHILDREN'S RESEARCH INSTITUTE 2017 - 2018
  • Chronobiology and Chronopharmacology to Prevent Sickle Cell Nephropathy  awarded by American Society of Hematology 2015 - 2018
  • Baby Hug Follow-Up Study II  awarded by University of Texas Southwestern Medical Center at Dallas 2013 - 2018
  • Private Grant  awarded by Pfizer Pharmaceuticals 2016 - 2017
  • The Kids - DOTT Trial  awarded by ALL CHILDREN'S RESEARCH INSTITUTE 2015 - 2017
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University 2013 - 2015
  • TCD with Transfusions Changing to Hydroxyurea  awarded by CINCINNATI CHILDREN'S HOSPITAL 2013 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Private Grant  awarded by TERUMO BCT, INC. 2012 - 2013
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University 2011 - 2013
  • Prevention of Stroke After STOP, A Retrospective Chart Review (Post STOP)  awarded by Medical University of South Carolina 2012 - 2013
  • TCD with Transfusions Changing to Hydroxyurea  awarded by Baylor College of Medicine 2011 - 2013
  • Baby HUG Follow-up Study II: Clinical Studies  awarded by University of Texas Southwestern Medical Center at Dallas 2012
  • Full Name

  • Jeanine Dumas